Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-β1/Smads Signaling in a Rat Model of Myocardial Infarction

[1]  Yue Xing,et al.  microRNA-378 promotes mesenchymal stem cell survival and vascularization under hypoxic–ischemic conditions in vitro , 2014, Stem Cell Research & Therapy.

[2]  R. Bauer,et al.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review , 2014, Biochemical pharmacology.

[3]  E. Andreeva,et al.  Mesenchymal stem cells and hypoxia: where are we? , 2014, Mitochondrion.

[4]  B. Gersh,et al.  Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. , 2014, Journal of molecular and cellular cardiology.

[5]  Minglong Chen,et al.  Cx43 in mesenchymal stem cells promotes angiogenesis of the infarcted heart independent of gap junctions. , 2014, Molecular medicine reports.

[6]  J. Martins,et al.  Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms , 2014, Stem Cell Research & Therapy.

[7]  Fang Liu,et al.  Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. , 2013, Journal of molecular and cellular cardiology.

[8]  K. Csiszȧr,et al.  Transcriptome Analysis of PPARγ Target Genes Reveals the Involvement of Lysyl Oxidase in Human Placental Cytotrophoblast Invasion , 2013, PloS one.

[9]  T. Soukup,et al.  Dietary omega-3 fatty acids attenuate myocardial arrhythmogenic factors and propensity of the heart to lethal arrhythmias in a rodent model of human essential hypertension , 2013, Journal of hypertension.

[10]  D. O’Toole,et al.  Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression. , 2013, Human gene therapy.

[11]  B. Hammock,et al.  A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. , 2013, International journal of cardiology.

[12]  Jagmeet P. Singh,et al.  Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. , 2013, The American journal of cardiology.

[13]  Jieyu Jiang,et al.  Cardiac Stem Cells and their Roles in Myocardial Infarction , 2013, Stem Cell Reviews and Reports.

[14]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.

[15]  M. Arévalo,et al.  L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. , 2013, Biochemical pharmacology.

[16]  N. Chattipakorn,et al.  Inhibition of p38 MAPK During Ischemia, But Not Reperfusion, Effectively Attenuates Fatal Arrhythmia in Ischemia/Reperfusion Heart , 2013, Journal of cardiovascular pharmacology.

[17]  G. Fishman,et al.  Designer gap junctions that prevent cardiac arrhythmias. , 2013, Trends in cardiovascular medicine.

[18]  Kevin H. Lin,et al.  PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha , 2013, Neuroscience.

[19]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[20]  Sushil K. Gupta,et al.  PPARγ Agonists Promote Oligodendrocyte Differentiation of Neural Stem Cells by Modulating Stemness and Differentiation Genes , 2012, PloS one.

[21]  Wanchun Tang,et al.  Effects of bone marrow mesenchymal stem cells in a rat model of myocardial infarction. , 2012, Resuscitation.

[22]  D. Rosenbaum,et al.  Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction. , 2012, Journal of the American College of Cardiology.

[23]  J. Kastrup,et al.  Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). , 2012, American heart journal.

[24]  J. D. de Bakker,et al.  Functional consequences of abnormal Cx43 expression in the heart. , 2012, Biochimica et biophysica acta.

[25]  M. Isobe,et al.  Different Roles of PPAR-&ggr; Activity on Physiological and Pathological Alteration After Myocardial Ischemia , 2012, Journal of cardiovascular pharmacology.

[26]  W. Degrave,et al.  Oral Administration of GW788388, an Inhibitor of Transforming Growth Factor Beta Signaling, Prevents Heart Fibrosis in Chagas Disease , 2012, PLoS neglected tropical diseases.

[27]  G. Fishman,et al.  Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells , 2012, Proceedings of the National Academy of Sciences.

[28]  M. Ashraf,et al.  Subcellular preconditioning of stem cells: mito-Cx43 gene targeting is cytoprotective via shift of mitochondrial Bak and Bcl-xL balance. , 2012, Regenerative medicine.

[29]  R. Zhao,et al.  JOURNAL OF HEMATOLOGY & ONCOLOGY REVIEW Open Access Clinical applications of mesenchymal stem cells , 2022 .

[30]  H. Krum,et al.  Short‐ and long‐term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST‐segment elevation myocardial infarction: a meta‐analysis of randomized control trials , 2012, European journal of heart failure.

[31]  J. Hare,et al.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. , 2011, Circulation research.

[32]  K. Segawa,et al.  Treatment of Human Mesenchymal Stem Cells with Angiotensin Receptor Blocker Improved Efficiency of Cardiomyogenic Transdifferentiation and Improved Cardiac Function via Angiogenesis , 2011, Stem cells.

[33]  Shao‐xin Zheng,et al.  Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction , 2011, Journal of cellular and molecular medicine.

[34]  A. James,et al.  Current methods of adipogenic differentiation of mesenchymal stem cells. , 2011, Stem cells and development.

[35]  K. Segawa,et al.  Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function , 2011, Stem cells.

[36]  J. García-Verdugo,et al.  Peroxisome proliferator‐activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo , 2011, Glia.

[37]  G. Fu,et al.  Down-regulation of connexin43 gap junction by serum deprivation in human endothelial cells was improved by (-)-Epigallocatechin gallate via ERK MAP kinase pathway. , 2011, Biochemical and biophysical research communications.

[38]  Periannan Kuppusamy,et al.  Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. , 2010, American journal of physiology. Cell physiology.

[39]  M. Barančík,et al.  Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: implication of intracellular coupling protein, connexin-43. , 2010, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[40]  Aleksey A. Porollo,et al.  Mitochondria-specific transgenic overexpression of connexin-43 simulates preconditioning-induced cytoprotection of stem cells. , 2010, Cardiovascular research.

[41]  M. Eijken,et al.  A New Concept Underlying Stem Cell Lineage Skewing That Explains the Detrimental Effects of Thiazolidinediones on Bone , 2010, Stem cells.

[42]  K. Cao,et al.  Connexin43 promotes survival of mesenchymal stem cells in ischaemic heart , 2010, Cell biology international.

[43]  D. Mabey,et al.  Neglected tropical diseases. , 2010, British medical bulletin.

[44]  C. Liang,et al.  Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products , 2009, British journal of pharmacology.

[45]  H. Haider,et al.  Sca-1+ Stem Cell Survival and Engraftment in the Infarcted Heart: Dual Role for Preconditioning-Induced Connexin-43 , 2009, Circulation.

[46]  Takao Masaki,et al.  PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β , 2009, Laboratory Investigation.

[47]  M. Heinrich,et al.  TGF-beta1 inhibits Cx43 expression and formation of functional syncytia in cultured smooth muscle cells from human detrusor. , 2009, European urology.

[48]  Guy Salama,et al.  Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia , 2007, Nature.

[49]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[50]  R. Srivastava.  Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. , 2011, Atherosclerosis.

[51]  Z. Karabekian,et al.  Stem Cell Rev and Rep , 2010 .

[52]  G. Heusch,et al.  Role of connexin 43 in ischemic preconditioning does not involve intercellular communication through gap junctions. , 2004, Journal of molecular and cellular cardiology.